Project
Boehringer Ingelheim BI1366-0031_456906_SSc
Ongoing - recruitment active ยท 2023 until 2026
Rubbert-Roth Andrea, Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2023
End Date
2026
Financing
Others
Brief description/objective
A Phase II, randomised, placebo-controlled, double-blind,
parallel-group, efficacy and safety study of at least 48 weeks of
oral BI 685509 treatment in adults with early progressive diffuse
cutaneous systemic sclerosis